Short answer
ACCENDRA HEALTH INC/VA/ (ACH) filed an 8-K current report with the SEC on October 9, 2026 reporting Item 3.01 (Notice of Delisting), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). NYSE deficiency: average closing price below $1.00 for 30 consecutive trading days.
- This filing includes Item 3.01, an item that often signal trouble.
ACCENDRA HEALTH INC/VA/ 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.01 · Notice of Delisting
- NYSE deficiency: average closing price below $1.00 for 30 consecutive trading days
- No immediate delisting: Common Stock remains listed, subject to other NYSE requirements
- Six-month cure period: closing price and 30-day average must each reach at least $1.00
- Company intends to notify NYSE within 10 business days and pursue compliance alternatives
- No immediate operating or SEC reporting impact, but potential future delisting risk for shareholders
Item 7.01 · Regulation FD Disclosure
- October 9, 2026 press release announces the event referenced in the preceding 8-K disclosure
- Exhibit 99.1 contains the substantive investor information and should be reviewed for market impact
Item EX-99.1 · Exhibit EX-99.1
- NYSE deficiency: 30-trading-day average closing price below $1.00
- No immediate delisting: ACH remains listed and trading during the cure period
- Six-month deadline to restore compliance, requiring $1.00 closing price and 30-day average
- Management considering alternatives, including a reverse stock split requiring stockholder approval by May 2027
- Share-price deficiency increases delisting risk and potential dilution or volatility from a reverse split
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ACCENDRA HEALTH INC/VA/ 8-K filings
Get the next ACH 8-K as it lands
Follow ACH for push alerts, or ask the research agent what this filing means.